Q4 2024 Novartis AG Earnings Call Transcript
Key Points
- Novartis AG (NVS) reported a strong financial performance for 2024, with a 16% increase in Q4 sales and a 29% rise in core operating income in constant currency.
- The company achieved a 12% sales growth and a 22% increase in core operating income for the full year, with a core margin reaching 38.7%, moving towards their goal of a 40% plus margin.
- Key products such as Entresto, Cosentyx, Kesimpta, and Kisqali showed significant sales growth, contributing to the company's robust performance.
- Novartis AG (NVS) has a promising pipeline with important approvals and submissions, including Kisqali for early breast cancer and Scemblix for CML, which are expected to drive future growth.
- The company is confident in its midterm guidance of 5% plus sales growth through 2029 and a 40% core margin by 2027, supported by strong in-market growth drivers and a deep pipeline.
- Novartis AG (NVS) faces potential loss of exclusivity for key products like Entresto in the US by mid-2025, which could impact sales and profitability.
- The company anticipates a modest headwind from Medicare Part D reforms, particularly affecting brands like Cosentyx and Kisqali.
- There is pressure on gross margins due to increasing royalties and potential generic competition, which may affect profitability.
- The competitive environment for products like Cosentyx is intensifying with new entrants, which could impact market share and growth.
- The delay in the Horizon Phase 3 trial for pelacarsen due to event rate dynamics raises concerns about the timeline for key pipeline readouts.
Good morning and good afternoon, and welcome to the Novartis Q4 2024 results release conference call and live webcast. (Operator Instructions) The conference is being recorded. (Operator Instructions) A recording of the conference call, including the Q&A session, will be available on our website shortly after the call ends.
With that, I would like to hand over to Ms. Sloan Simpson, Head of Investor Relations. Please go ahead, madam.
Thank you, Sharon. Good morning and good afternoon, everyone, and welcome to our Q4 and full year 2024 earnings call.
The information presented today contains forward-looking statements that involve known and unknown risks, uncertainties, and other factors. These may cause actual results to be materially different from any future results, performance, or achievements expressed or implied by such statements. For a description of some of these factors, please refer to the company's Form 20-F and its most recent quarterly results on Form 6-K that
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
